Median bone marrow involvement decreased from 60 percent to 25 percent , and the median hemoglobin level increased from 10.5 g per deciliter to 13.8 g per deciliter during best response . Discordance between serum IgM amounts and bone marrow involvement was noticed at six months , though by 12 months and two years , a stronger correlation of the variables was evident. Responses included an excellent partial response in 10 individuals, a partial response in 36 sufferers, and a response in 11 patients, representing overall and major responses of 90.5 percent and 73.0 percent , respectively. The median situations to at least small and partial responses had been four weeks and 8 weeks, respectively.Previous research has shown that treatment with daclizumab decreased multiple sclerosis disease activity, says John W. Rose, M.D., professor of neurology at the University of Utah College of Medicine, Neurovirology Study Laboratory, Veterans Affairs Salt Lake Town Health Care Program and the University of Utah, an author on the study. Our work in the CHOICE trial implies that daclizumab considerably reduces MS lesion development in people who have active relapsing disease.